PubMed HealthSearch

PubMed · 740722

[Arterial claudication].

Abstract

The authors recall that in their report presented to the 79th French Congress of Surgery (September, 1977), they included the results of 26,632 chronic obstructive arteriopathies, 49.8% of them at the intermittent claudication stage. Medical treatment was initially proposed in 27% of cases. The results were followed up in 1,660 patients. At term (8 years and more), there were good results in only one third of the patients, and 28% of the patients had to be operated on. Lumbar sympathectomy was practiced on an isolated basis in 35% of cases. At the cost of a minimal (0.7%) mortality rate, with improvement beyond eight years in 61.5% of patients, and only 19% having to undergo direct revascularization. Direct revascularization was proposed in 38% of cases. At the aorto-iliac stage, thrombo-endarterectomies and single and bi-lateral prothetic bridgings gave very similar results: a mortality rate of 3.4% on the average, with good results beyond eight years in 76.6% of patients. Direct revascularizations are practiced almost as often on the femoro-popliteal level for simple intermittent claudications. Mortality is low (1%), and the long-range results similar (76.4% of good results beyond 8 years), but the installation of a prothesis at the femoro-popliteal stage so often fails that it should not be done if the intermittent claudication is tolerable. Surgery plays a prime role in the treatment of claudications of arterial origin, a role that the success and the continuation of the good results, when applied under the proper conditions, amply justifies.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J B Levy, A Gedeon. [Arterial claudication].. https://pubmed.ncbi.nlm.nih.gov/740722/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Adrenal steroid receptor activation in rat brain and pituitary following dexamethasone: implications for the dexamethasone suppression test.

The dexamethasone suppression test (DST) has been used extensively to evaluate feedback inhibition of the hypothalamic-pituitary-adrenal (HPA) axis by adrenal steroids. Nevertheless, it remains unclear at what level of the HPA axis and through which adrenal steroid receptor subtype dexamethasone exerts its inhibitory effect. Because adrenal steroid receptor activation is an important prerequisite for dexamethasone to affect cellular function, HPA axis tissues that exhibit evidence of receptor activation following dexamethasone administration are likely site(s) of action for this synthetic hormone to inhibit HPA axis activity. Therefore, type-I and type-II adrenal steroid receptor activation was assessed in the pituitary, hypothalamus, and hippocampus of intact and adrenalectomized rats after overnight exposure to various oral doses of dexamethasone. Results with dexamethasone were compared to similar studies using corticosterone, the endogenous glucocorticoid of the rat. All dexamethasone doses led to significant type-II receptor activation in the pituitary, whereas only an exceedingly high dexamethasone dose activated type-II receptors in the hippocampus and hypothalamus. Dexamethasone had little effect on type I receptors in any tissue at any dose. In contrast, corticosterone significantly activated type-I receptors in all tissues, whereas it activated type-II receptors in the brain and not the pituitary at physiological concentrations. Because dexamethasone activated pituitary type-II receptors at blood concentrations that did not activate type-II receptors in the brain, these results suggest that the DST in humans may primarily be a measure of type-II adrenal steroid receptor feedback inhibition at the level of the pituitary.

Adrenalectomy

Immunocytochemical and in situ hybridization detection of hypothalamic neuropeptides from postmortem unfixed rat brains.

The effects of postmortem delay on neuropeptide-containing perikarya was studied in the paraventricular nucleus (PVN) of the rat hypothalamus. Serial sections from brains kept in the skull after death for 6 h and immunocytochemically processed for oxytocin (OT), vasopressin (AVP) and corticotropin releasing factor (CRF) or hybridized in situ for CRF resulted in the well preserved phenotypic expression and stability of mRNA of the aforementioned neuropeptides. Furthermore in most cases, AVP and CRF expression was discernibly enhanced relative to prefixed immunopositive tissue. Results of this study suggest that postmortem variables do not significantly alter the neurochemical coding of magnocellular or parvocellular neurosecretory systems, and support the view that rat and human brain topography can be investigated from tissue left in situ after death for a relatively long period of time.

Adrenalectomy

Adrenalectomy does not change CRF secretion induced by interleukin-1 from rat perifused hypothalami.

Interleukin-1 (IL-1) is a potent hypothalamic-pituitary-adrenal (H-P-A) axis activator. The hypothalamus is considered one of the main sites of action of IL-1 on the H-P-A axis, inducing CRF secretion, which is modulated by glucocorticoids. Glucocorticoids, which modulate CRF release by a negative feedback inhibition, have been postulated to exert a permissive action on the IL-1 effect on CRF secretion. Using a continuous perifusion system of rat hypothalami, the results of the present study indicate that at the same concentrations, IL-1 beta exerted a more potent effect than IL-1 alpha stimulating CRF secretion. The increase in hypothalamic CRF release induced by IL-1 was rapidly inhibited by both dexamethasone and corticosterone. However, adrenalectomy 2 or 8 days before did not modify CRF secretion induced by IL-1 from the in vitro perifused hypothalami. These data indicate that IL-1 does not seem to induce CRF secretion by interfering with an impeding action of glucocorticoids, although the cytokine effect is negatively modulated by corticosteroids.

Adrenalectomy